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Summary 
The discovery and synthesis of new tyrosine-based inhibitors of DNA gyrase B (GyrB), that target its ATPase 
subunit, is reported. 24 compounds were synthesized and evaluated for activity against DNA gyrase and DNA 
topoisomerase IV. Antibacterial properties of selected GyrB inhibitors have been demonstrated by their activity 
against S. aureus and E. faecalis in the low micromolar range. The most promising compounds, 8a and 13e, inhibited 
E coli and S. aureus GyrB with IC50 values of 40 and 30 µM. The same compound also inhibited the growth of S. 
aureus and E. faecalis with minimal inhibitory concentrations (MIC90) of 14 and 28 µg mL-1, respectively. 
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Introduction 
DNA gyrase and topoisomerase IV (topo IV) are clinically validated targets that catalyze reactions involving the 
transient break of both strands of DNA in an ATPase-dependent manner.[1,2] Negatively supercoiled DNA is crucial 
for cell processes including DNA replication, transcription, and recombination, making both enzymes essential for 
bacterial survival. DNA gyrase is primarily responsible for initiation of DNA replication, elongation and introduction 
of negative supercoils in front of the replication fork thereby relieving torsional strain during replication. Topo IV is 
primarily involved in the control of DNA supercoiling and in the decatenation of daughter chromosomes after DNA 
replication. [3] 
DNA gyrase exists as a heterotetrameric complex similar to that of topo IV, being composed of two pairs of GyrA 
and GyrB subunits homologous to two pairs of ParC and ParE subunits of topo IV, respectively. Fluoroquinolones 
are currently the only clinically relevant inhibitors of the two enzymes.[4] They bind at the interfaces between the 
GyrA subunits in gyrase and ParC subunits in topoisomerase IV, stabilizing the covalent enzyme-DNA complexes 
and leading to the termination of replication cycle and cell death.[5] Despite the clinical and commercial success of 
fluoroquinolones, their use nowadays is limited due to some serious side effects and, especially, to the emergence of 
fluoroquinolone-resistant bacteria.[6,7] Surprisingly, ATPase activity of bacterial DNA gyrase that resides in the 
GyrB/ParE subunit remains so far pharmacologically underexploited, even though it is effectively targeted by 
aminocoumarin natural products such as clorobiocin and novobiocin (Figure 1), the former being introduced into the 
clinic in the 1960s.[8,9] In the last ten years, interest in the design of novel small molecular inhibitors of gyrase ATP 
subunit has intensified, partially because of the elucidation of many crystal structures by X-ray crystallography. A 
wide variety of new low molecular weight ligands that compete with the binding of ATP to GyrB have been 
synthesized and shown to exhibit antibacterial activity, however none have yet progressed into the clinic.[10,11] 
Antibacterial compounds that target the ATP-binding site of GyrB have a great potential because of the latter’s 
essentiality and presence only in bacterial cells. In addition, it has been demonstrated that ATP competitive inhibitors 
are likely to avoid cross-resistance with fluoroquinolones, making them interesting candidates for the fight against 
fluoroquinolone resistant pathogens.[5,12] 
 
  
Figure 1. Representative examples of oroidin and GyrB inhibitors. 
 
Pyrrolecarboxamide-containing compounds such as oroidin[13] (Figure 1) are widely present in sponge-derived 
marine natural products, many of them exhibiting diverse biological activities, for example modulatory activity on 
voltage-gated sodium channels[14,15] and biofilm formation.[16,17] In addition, ester isosteres of 
pyrrolecarboxamide are present in a class of naturally occurring antibiotics clorobiocin and coumermycin A1, 
produced by Streptomyces strains, which inhibit bacterial type IIA topoisomerases. The strategy of incorporating 
substituted pyrroleamides was applied in the design of low-molecular weight inhibitors of GyrB in fragment-based 
NMR screening by AstraZeneca.[18] The continuation of their research gave a series of potent pyrroleamide 
derivatives;AZD5099 progressed to phase 1 human clinical trial but was withdrawn in 2012 due to safety and 
efficacy reasons (Figure 1).[18-21] Other potent GyrB inhibitors with the 1H-pyrrole-2-carboxamide moiety, such as 
N-phenyl-4,5-dibromopyrroleamides, N-phenylindolamides[22-24] and 4,5,6,7-tetrahydrobenzo[1,2‑d]thiazoles,[25] 
were reported by our research group recently. However, none of them displayed any significant antibacterial activity. 
We describe here the discovery of two series of compounds, containing the 1H-pyrrole-2-carboxamido-tyrosine 
moiety, which inhibit the ATPase activity of DNA-gyrase B and have antibacterial activity. The general strategy for 
their design is depicted in Figure 2. We postulated that it might be possible to obtain an inhibitor of gyrase ATPase 
subunit using only two diversification points at a pyrroleamide fragment and a substituted aromatic amine fragment 
linked to a central amino acid moiety. Importantly, because of its synthetic simplicity, this amino acid linker would 
provide access to various structure activity relationship (SAR) and optimization opportunities (Figure 2). According 
to our model and on the basis of inhibitors from the literature,[12] the pyrroleamide was thought to be involved  as 
both H-bond acceptor and H-bond donor in hydrogen bonds to an active-site Asp73 and a tightly bound water 
molecule in the active site of the enzyme. This binding pattern mimics the binding of the adenine of ATP as 
determined by X-ray crystallography.[26] 
Next, we introduced various aromatic fragments R3 that could extend outside the ATP binding pocket and form 
additional cation-π interactions with the highly conserved Arg136 residue localized at the entry of the ATP-binding 
pocket and/or could be involved in hydrogen bonding interactions with Arg76 in the proximity of the first arginine 
residue. This region of the enzyme differs from that in its mammalian homologues as well as from other ATPases of 
the GHKL protein family. In addition, binding of an inhibitor to this region has an effect that differs importantly from 
that caused by ATP binding, enabling selectivity makes an important difference compared to ATP-binding and 
enables selectivity of designed inhibitors towards a myriad of ATP utilizing enzymes. These predicted interactions of 
both moieties are conserved across known GyrB inhibitors.[27] 
Lastly, the bulky and hydrophobic tyrosine was applied as an amino acid linker which could extend into a more open 
and hydrophobic region of the ATP ribose ring binding pocket and may be involved in hydrogen bonding interactions 
between the phenolic OH group and one of the a two arginines (Arg76 and Arg136) in the binding site. 
  
 
Figure 2. Structure and modifications of the designed inhibitors. 
Our preliminary docking studies suggested 1H-pyrrolecarboxamide to be crucial for binding into the adenine binding 
pocket. The role of substituents on pyrrole functionality in binding is, on the one hand, to occupy the hydrophobic 
pocket of the enzyme and, on the other hand, to increase the acidity of the pyrrole NH group and thus strengthen the 
interaction with Asp73. It was therefore expected that varians of the 1H-pyrrole ring substituents would have great 
influence on the GyrB inhibitory activity. The preparation of the first series of designed inhibitors thus started with 
optimization of the 1H-pyrrolecarboxamide fragment, while keeping the aminophenyl moiety fixed. Furthermore, 
other heterocycles, such as indole and indazole, were also installed in this position instead of the pyrrole to increase 
binding energy by occupying a larger space of the adenine binding pocket. 
Results and discussion 
Preparation of the first series is presented in Scheme 1. Esters 8a-f were synthesized in four steps, starting from L-
Tyr (4), which was protected with the tert-butoxycarbonyl (Boc) group.[28] The N-protected derivative 5 was then 
coupled to methyl 3-aminobenzoate, using DCC and HOBt[29] as activating agents at 0°C, to form 6 which was 
further deprotected with a solution of HCl gas in THF to form the  salt 7that precipitated from the reaction mixture. 
Compound 7 then reacted with the corresponding 2-trichloroacetyl- 1H-pyrrole derivatives, using Na2CO3 as a base 
in DMF at 40°C, to give 8a, 8c and 8d. However, the reaction with 4,5-dichloro-2-trichloroacetyl-1H-pyrrole did not 
proceed well and a mixture of products that were hard to purify was obtained. The 4,5-dichloro-1H-pyrrole-2-
carboxylic acid was therefore used, successfully, in the coupling reaction with 7 using EDC, HOBt and NMM in 
DMF to give 8b. The same coupling procedure, using indole-2-carboxylic and indazole-3-carboxylic acid, was also 
successfully used in the preparation of 8e and 8f, respectively. Hydrolysis of 8a-f with 2M LiOH in H2O/THF led to 
the corresponding acids 9a-f. 
Six esters 8a-f and their corresponding carboxylic acids 9a-f were evaluated on the E.coli gyrase inhibition assay. 
The results are presented in Table 1 as IC50 values. Of 12 compounds tested only dibromo and dichloro derivatives 
8a, 9a and 9b displayed activity against E. coli gyrase with IC50 values of 40, 16 and 24 µM, respectively. In general, 
the dibromopyrrole gave a better inhibition than a dichloropyrrole which is most apparent when active and inactive 
esters 8a and 8b are compared. The difference, however, is not so pronounced when the two acidic counterparts, 9a 
and 9b, are compared, only a small difference in activity,that falls within the limits of experimental error, is 
observed. The nitro derivatives 8c,d and 9c,d, which were prepared with the aim of improving the interaction with 
Asp73 by increasing the acidity of the pyrrole NH group, were completely inactive at concentrations below 250 µM. 
This indicates the importance of hydrophobic interactions between the pyrrole ring and the hydrophobic binding 
pocket. Furthermore, the results indicate that the bulkier indole and indazole groups were unable to optimally occupy 
the hydrophobic binding pocket, thus making the interactions of compounds 8e,f and 9e,f with Asp73 less strong. In 
addition, compounds 9a and 9b, with a free carboxylic acid group, were more potent than esters 8a and 8b. Both of 
  
these findings are in agreement with those from our previous study.[22] Importantly, measurements of Kd with the 
surface plasmon resonance assay (SPR) on G24 protein, which is the smallest fragment of the N terminal part of the 
B subunit still able to bind the ATP molecule,[28] gave results for 8a (Kd = 46 µM) similar to the IC50 value (40 µM) 
from our screening test, which indicates the specificity of binding into the active site of the enzyme.  
Having defined 4,5-dibromopyrrolecarboxamide as a promising moiety which enables strong binding into the 
adenine binding pocket, variations in aminobenzoic part of molecule 9a were investigated. Compounds with different 
aliphatic and aromatic functionalities in place of aminobenzoic acid were prepared in four steps according to Scheme 
2. First attempts to prepare 11 from Tyr-OMe hydrochloride (10) and 4,5-dibromo-2-trichloroacetyl-1H-pyrrole were 
not successful. Compound 11 was therefore prepared from 4,5-dibromo-1H-pyrrole-2-carboxylic acid using EDC and 
HOBt as activating agents. The ester 11 was further hydrolyzed to carboxylic acid 12 which was readily coupled with 
various aliphatic amines under mild reaction conditions using EDC and HOBt at 0°C to give esters 13a-d and 13h. 
On the other hand, aromatic amines, being much less nucleophilic, required heating at 60°C to obtain 13e-g as 
racemic mixtures in much lower yields than those for their aliphatic counterparts 13a-d and 13h. The esters 13a-e 
were hydrolyzed with LiOH to obtain carboxylic acids 14a-e. 
 
Scheme 1. Reagents and conditions: (i) Boc2O, dioxane/water 1/1, 0°C, 24h, 90%; (ii) methyl 3-aminobenzoate, 
DCC, HOBt, CH2Cl2/DMF  1/1, 0°C to r.t., 24h, 56%; (iii) HCl(g), THF, 0°C, 20 min, 98%; (iv) for 8a,8 c, 8d: 
RCOCCl3, Na2CO3, DMF, 40°C, 24h, 20-74%; (v) 4,5-dichloro-2-trichloroacetyl-1H-pyrrole (for 8b), indole-2-
carboxylic acid (for 8e), indazole-3-carboxylic acid (for 8f), EDC, HOBt, NMM, DMF, 0 °C to r.t., 24h, 39–50%; 
(vi) 2M LiOH, H2O/THF=1/1, r.t., 2.5h, 95%.
  
Table 1. Inhibitory activities against E. coli and S. aureus DNA gyrase. 
Table 2. Antibacterial activities.  
According to our model (Figure 2), the benzoate moiety should bind in the proximity of both 
arginines. Different types of interactions between inhibitors and the two arginines (Arg76 and Arg136) 
have been described.[12] The majority of published compounds have an aromatic ring at this position 
which forms cation-π interactions with at least one of two arginines and/or a functional group which 
forms proton donor-acceptor type of interaction with one of arginines. To evaluate the importance of 
π-stacking interactions in our compounds and to potentially improve the activity, in addition to 
benzoate, phenol and phenyl groups in position R different aliphatic esters 13a-c, carboxylic acids 
14a-c and amide 13h were used. In addition, two dicarboxylic acid esters 13b,13c were prepared to 
obtain interactions with both arginines. However, the results of E. coli gyrase inhibition assays, 
presented in Table 1, were disappointing. With the exception of aspartate derivative 13b and amide 
13h all compounds of this type showed IC50 values far above 50 µM, which confirmed the importance 
of π-stacking interactions for inhibitory activity. Surprisingly, it was demonstrated that the presence of 
a -COOH group on the aromatic ring has a detrimental effect on the activity and indicated that these 
compounds do not form proton donor-acceptor interaction of the carboxyl group with one of two 
arginines. Indeed, when a COOH group was replaced with a OH group (compound 13f), or was absent 
(compound 13g), the activity improved to 13 µM and 1.9 µM, respectively. Even when the -COOH 
group was positioned next to a -OH group (compounds 13e and 14e), the inhibitory activity on E. coli 
gyrase was still lower than those for 13f and 13g. These results indicate that the interactions of the 
phenylcarboxylic moiety are mostly of a cation-π stacking nature. Lastly, the ester 13d and carboxylic 
acid 14d in which a methylene group was inserted between the phenyl ring and the amino group 
inhibited the E.coli enzyme with 0.97 µM and 0.62 µM, respectively.  
Compounds which were active against E. coli gyrase were then selected for testing against gyrase 
from S. aureus. Only 13f displayed a significant inhibitory activity, with an IC50 value of 28 µM. 
Compounds 8a, 13f, 14d and 14e, which were all active against E. coli gyrase, were then tested 
against E. coli and S. aureus topoisomerase IV but were found to be inactive at concentrations below 
100 µM. A dual targeting intracellular inhibitor of both enzymes GyrB and ParE would be expected to 
show lower frequency of resistance and larger antibacterial potency.[30] Given the apparent similarity 
between GyrB and ParE, particularly in the amino acids making crucial interactions with current 
inhibitors, the selectivity for GyrB may be surprising. On the other hand, our results are in agreement 
with those of Eakin et al[18] who also observed similar selectivity of pyrroleamide inhibitors. It 
  
appears that subtle conformational changes or dynamic differences between the two enzymes could 
result in the observed differences in activities.  
The antimicrobial activities of all active compounds with E. coli IC50 activity equal to or below 50 µM 
were evaluated against two Gram-positive (S. aureus ATCC 25923, E. faecalis ATCC 292122) and 
three Gram-negative (E. coli ATCC 25922, ΔtolC, ΔimpA) strains. Three promising compounds, 8a, 
13e and 13f, were identified, all of which possessed modest antibacterial activity against both S. 
aureus and E. faecalis (Table 1). Compounds 8a and 13e, which were the most potent, inhibited S 
aureus and E. faecalis with MIC90 values of 14 and 28 µg mL-1. However, when the activities of both 
8a and 13e against S. aureus are compared to their IC50 activities there is no clear correlation between 
enzymatic and antibacterial activity. Several literature examples[19,21,31-37] indicate, with some 
notable exceptions,[18,38] that nanomolar inhibition of GyrB is required for antibacterial activities 
comparable to our results. The discrepancy in correlation between enzymatic and antibacterial activity 
could indicate that their antibacterial properties are not just a consequence of GyrB inhibitory activity 
but most probably also of additional mechanism. Furthermore, the higher antibacterial activities of 
ester 8a and 13e compared to their acidic counterparts 9a and 14e could be attributed to insufficient 
penetration of compounds 9a and 14e through the bacterial cell wall due to their acidic nature.[39] 
These results are in accordance with the recently reported correlation on S. pneumoniae between 
activity (pMIC) of compounds and their pKa.[40] However, none of the compounds evaluated 
possessed any inhibitory activity against wild-type E.coli at concentrations below 250 µM. Additional 
evaluation against ΔtolC and ΔimpA E. coli strains suggests that some of them (13d, 13e and 13f) are 
efflux pump substrates and 13e and 13f do not possess the physicochemical properties necessary for 
cell wall penetration in E. coli.  
	
Scheme 2. Reagents and conditions: (i)4,5-dibromopyrrole-2-carboxylic acid, EDC, HOBt, NMM, 
DMF, 0 °C to r.t., 16h, 79%; (ii) LiOH, H2O/THF = 1/1, r.t., 1.5h, 95%; (iii) for 13a-d, 13h: R1NH2, 
EDC, HOBt, NMM, DMF, 0 °C to r.t., 16h, 45-75%, (iv) for 13e-g: Ar-NH2, EDC, HOBt, DMAP, 
NMM, DMF, 0 °C, 20 min to 60 °C, 16h, 14-53%; (v) 2M LiOH, H2O/THF, 25 °C, 24h, 95%. 
Conclusion 
In conclusion, the design, synthesis and biological evaluation of a new class of tyrosine-based 
diamides as potential DNA gyrase B inhibitors is reported. The compounds displayed sub-micromolar 
to low micromolar IC50 values against E. coli gyrase. In addition, three compounds with antibacterial 
activity were discovered. The most promising compounds, 8a and 13e, inhibited the growth of S. 
aureus and E. faecalis with minimal inhibitory concentrations (MIC90) of 14 and 28 µg mL-1. All three 
  
compounds still have antibacterial activities much lower than that of ciprofloxacin, but provide a good 
rationale for further optimization of this class of compounds towards more potent DNA gyrase and 
topoisomerase IV inhibitors with even better antibacterial activity. 
Chemistry 
General 
Chemicals were obtained from Acros, Aldrich Chemical Co., and Fluka and used without further 
purification. Analytical TLC was performed on silica gel Merck 60 F254 plates (0.25 mm), using 
visualization with UV light and ninhydrin. Column chromatography was carried out on silica gel 60 
(particle size 240–400 mesh). HPLC analyses were performed on an Agilent Technologies 1100 
instrument with a G1365B UV-VIS detector, a G1316A thermostat and a G1313A autosampler using a 
Phenomenex Luna 5 µm C18column (4.6 × 150 mm or 4.6 × 250 mm) and flow rate of 1.0 mL/min. 
The eluent consisted of trifluoroacetic acid (0.1% in water) as solvent A and methanol or acetonitrile 
as solvent B. Melting points were determined on a Reichert hot stage microscope and are uncorrected. 
1H NMR and 13C NMR spectra were recorded at 400 and 100 MHz, respectively, on a Bruker 
AVANCE III 400 spectrometer in DMSO-d6, CDCl3 or MeOH-d4 solution, with TMS as the internal 
standard. IR spectra were recorded on a Perkin-Elmer Spectrum BX FT-IR spectrometer or Thermo 
Nicolet Nexus 470 ESP FT-IR spectrometer. Mass spectra were obtained using a VGAnalytical 
Autospec Q mass spectrometer. Optical rotations were measured on a Perkin-Elmer 241 MC 
polarimeter. The reported values for specific rotation are average values of 10 successive 
measurements using an integration time of 5 s. The purity of the tested compounds was established by 
HPLC using Agilent EclipsePlus C18 column 4.6 mm x 150 mm, flow rate: 1.0 mL/min; injection 
volume 5 µl: Optical purity of the tested compounds was established by HPLC using. Kromasil 3-
Cellucoat column; 150x4.6 mm, flow rate: 1.0 mL/min; injection volume 5 µl.  
Some NMR spectra as well as the InChI codes of the investigated compounds are provided as 
Supporting information. 
Boc-L-tyrosine (5)[41]  
L-tyrosine (8.80 g, 48.6 mmol) and NaOH (3.89 g, 97.2 mmol) were dissolved in a mixture of 1,4-
dioxane (100 mL) and water (100 mL). The solution was cooled to 0°C prior to the addition of Boc2O 
(10.64 g, 48.6 mmol). After 48 h concentrated hydrochloric acid was added until pH = 1 was reached, 
then the resulting solution was extracted with EtOAc (3x 100 mL). Combined organic fractions were 
washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure to yield white 
crystals. 1H-NMR (CDCl3, 400 MHz): δ 1.40 (s, 9H, Boc-CH3), 2.98 (dd, J = 14.0, 6.0 Hz, 1H, benzyl-
  
CH2), 3.02 (dd, J = 14.0, 6.0 Hz, 1H, benzyl-CH2), 4.53 (ddd, J = 8.4, 6.0, 6.0 Hz, 1H, Tyr-α-CH, 5.10 
(d, J = 8.4 Hz, 1H, NH), 6.69 (d, J = 8.2 Hz, 2H, ArH), 6.95 (d, J = 8.2 Hz, ArH), 7.6 – 9.2 (bs, 2H, 
OH and COOH) ppm.  
(S)-methyl 3-(2-((tert-butoxycarbonyl)amino)-3-(4-hydroxyphenyl)propanamido) benzoate (6) 
Boc-L-tyrosine (5.03 g, 17.9 mmol), methyl 3-aminobenzoate[42] (5.39 g, 35.8 mmol) and 1-
hydroxybenzotriazole were dissolved in a mixture of 15 ml of dichloromethane and 15 ml of DMF and 
cooled to 0°C prior to the addition of N,N’-dicyclohexylcarbodiimide (5.54 g, 26.9 mmol). The 
resulting solution was allowed to warm to room temperature during 24 h. The solvents were 
evaporated under reduced pressure and the residue dissolved in EtOAc (100 mL). The solution was 
washed with 10% water solution of citric acid (2x50 mL), saturated water solution of NaHCO3 (2x50 
mL) and brine (50 mL). Organic phase was dried over Na2SO4, filtered and concentrated under 
reduced pressure. Crude product was purified by flash column chromatography (n-hexane : EtOAc = 1 
: 1) to yield pale pink powder. Yield 56%, mp 187°C. 1H NMR (DMSO-d6, 400 MHz): δ 1.33 (s, 9H, 
Boc-CH3), 2.73 (dd, J = 13.8, 9.7 Hz, 1H, benzyl-CH2), 2.87 (dd, J = 13.8, 4.8 Hz, 1H, benzyl-CH2), 
3.86 (s, 3H, Me-ester-CH3), 4.22 (ddd, J = 9.7, 7.9, 4.8 Hz, 1H, Tyr-α-CH), 6.65 (d, J = 8.5, 2H, ArH), 
7.09 (d, J =7.9 Hz, 1H, Boc-NH), 7.10 (d, J =8.5, 2H, ArH), 7.46 (t, J = 7.9, 1H, ArH), 7.64 (dt, J = 
7.9, 1.7 Hz, 1H, ArH), 7.85 (dd, J = 7.9, 1.7 Hz, 1H, ArH), 8.25 (dd, 1.7, 1.7 Hz, 1H, ArH), 9.19 (s, 
1H, phenol-OH), 10.23 (s, 1H, Ar-amide-NH) ppm. 13CNMR (DMSO-d6, 100 MHz): δ 28.19, 36.58, 
52.24, 57.07, 78.12, 114.85, 119.72, 123.70, 123.85, 127.87, 129.28, 130.08, 130.16, 139.36, 155.43, 
155.83, 166.08, 171.36 ppm. MS (ESI): m/z 413.2 ([MH]-, 100). HRMS (ESI) for C22H25N2O6: 
calculated, 413.1718; found, 413.1721. [𝛼]$%& = -49.1 (c 1.00, MeOH). RP-HPLC purity: 98.5%. 
(S)-3-(4-hydroxyphenyl)-1-((3-(methoxycarbonyl)phenyl)amino)-1-oxopropan-2-aminium chloride (7) 
Compound 6 (1.63 g, 3.92 mmol) was dissolved in THF (40 mL) and bubbled for 20 min with 
anhydrous HCl gas on ice bath. After the addition of diethylether (100 mL) white precipitate was 
formed, which was filtered, dried in vacuum for 1 h and stored in desiccator. Yield 98%, mp: 140 – 
145°C. 1H NMR (DMSO-d6, 400 MHz): δ 3.01 (dd, J = 13.8, 7.3 Hz, 1H, benzyl-CH2), 3.12 (dd, J = 
13.8, 6.5 Hz, 1H, benzyl-CH2), 3.86 (s, 3H, Me-ester-CH3), 4.2 (bs, 1H, Tyr-α-CH), 6.70 (d, J = 8.5, 
2H, ArH), 7.10 (d, J = 8.5, 2H, ArH), 7.50 (dd, J = 8.1, 7.8 Hz,  1H, ArH), 7.69 (ddd, J = 7.8, 1.6, 1.0 
Hz, 1H, ArH), 7.85 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H, ArH), 8.26 (dd, J = 2.1, 1.8 Hz, 1H, ArH), 8.4 (bs, 
3H, NH3), 9.41 (s, 1H), 11.14 (s, 1H) ppm. 13C NMR (DMSO-d6, 100 MHz): δ 36.19, 52.32, 54.56, 
115.36, 120.00, 124.02, 124.66, 129.48, 130.22, 130.52, 138.46, 138.51, 156.58, 165.94, 167.24 ppm. 
MS (ESI): m/z 315.1 ([MH]+, 100). HRMS (ESI) for C17H19N2O4: calculated, 315.1339; found, 
315.1339. [𝛼]$%& = -35.6 (c 0.60, MeOH). RP-HPLC purity 97.4% 
  
General procedure for the preparation of methyl benzoates 8a, c and d.  
Compound 7 (1 eq.) and Na2CO3 (1.1 eq.) were dissolved in DMF (1mL/mmol) under Ar atmosphere 
and heated to 40°C. A solution of 2-trichloroacetyl-1H-pyrrole derivative in DMF (1mL/mmol) was 
subsequently added dropwise during 30 min and stirred for 18h at 45°C. The reaction mixture was 
then concentrated, dissolved in EtOAc and washed with 10% solution of citric acid, 1 M NaOH and 
brine successively. Organic phase was dried over Na2SO4, filtered and concentrated.  
(S)-methyl 3-(2-(4,5-dibromo-1H-pyrrole-2-carboxamido)-3-(4-hydroxyphenyl)propanamido)benzoate 
(8a)	
Compound 8a was prepared from 7 and 2,2,2-trichloro-1-(4,5-dibromo-1H-pyrrol-2-yl)ethan-1-one 
and recrystallized from n-hexane/EtOAc mixture to give the title compound as brownish crystals. 
Yield 20%. mp 126 – 132°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.88 (dd, J = 13.8, 10.0 Hz, 1H, 
benzyl-CH2), 3.01 (dd, J = 13.8, 4.9 Hz, 1H, benzyl-CH2), 3.85 (s, 3H, Me-ester-CH3), 4.68 (ddd, J = 
10.0, 8.1, 4.9 Hz, 1H, Tyr-α-CH), 6.64 (d,  J = 8.5 Hz, 2H, phenol-2,4-H), 7.07 (d, J = 2.7 Hz, 1H, 
ArH), 7.14 (d, J = 8.5 Hz, 2H, ArH), 7.47 (dd, J = 8.1, 7.9 Hz, 1H, ArH), 7.65 (ddd, J = 7.9, 1.6, 1.0 
Hz, 1H, ArH), 7.86 (ddd, J = 8.1, 2.1, 1.0 Hz, 1H, ArH), 8.26 (dd, J = 2.1, 1.6 Hz, 1H, ArH), 8.37 (d, J 
= 8.1 Hz, 1H, amide-NH), 9.19 (s, 1H, Ar-amide-NH), 10.39 (s, 1H, phenol-OH), 12.64 (d, J = 2.7, 
1H, pyrrole-NH) ppm. 13C NMR (DMSO-d6, 100 MHz): δ 37.23, 41.89, 52.11, 100.23, 102.44, 
105.24, 114.93, 115.04, 124.99, 126.94, 127.16, 127.33, 128.11, 129.16, 130.27, 144.77, 156.03, 
157.32, 166.10, 170.70 ppm. MS (ESI): m/z 562.0 ([MH]-, 51), 563.9 ([MH+2]-,100), 566.0 ([MH-2]-, 
49). HRMS (ESI) for C22H18N3O5Br2: calculated, 561.9619; found, 561.9599. [𝛼]$%& = -93.1 (c 0.36, 
MeOH). RP-HPLC purity: 96%. ee = 92%. 
(S)-methyl 3-(3-(4-hydroxyphenyl)-2-(5-nitro-1H-pyrrole-2-carboxamido)propanamido)benzoate (8c)	
Compound 8c was prepared from 7 and 2,2,2-trichloro-1-(5-nitro-1H-pyrrol-2-yl)ethan-1-one to yield 
orange powder. Yield 60%, mp 124°C, 1H NMR (MeOH-d4, 400 MHz): δ 3.04 (dd, J = 13.8, 8.2 Hz, 
1H, benzyl-CH2), 3.17 (dd, J = 13.8, 7.1 Hz, 1H, benzyl-CH2), 3.90 (Me-ester-CH3), 4.83 (dd, J = 8.2, 
7.1 Hz, 1H, Tyr-α-CH), 6.68 (d, J = 8.5 Hz, 2H, ArH), 6.90 (d J = 4.3 Hz, 1H, ArCH), 7.07 (d, J = 4.3 
Hz, 1H, ArCH), 7.12 (d, J = 8.5 Hz, 2H, ArH), 7.41 (dd, J = 8.2, 7.7 Hz, 1H, ArH), 7.73 (ddd, J = 8.2, 
2.3, 1.1 Hz, 1H, ArH), 7.75 (ddd, J = 7.7, 1.7, 1.1 Hz, 1H, ArH), 8.19 (dd, J = 2.3, 1.7 Hz, 1H, ArH) 
ppm. 13C-NMR (DMSO-d6, 100MHz): δ 36.74, 52.22, 55.66, 110. 92, 113.15, 114.83, 114.98, 119.89, 
123.83, 124.09, 127.41, 129.30, 130.07, 138.61, 139.10, 155.89, 166.01, 170.36 ppm. IR (ATR): ν 
3281, 3143, 2952, 1702, 1637, 1556, 1514, 1443, 1290, 1236, 1204, 1106, 808, 754, 681 cm-1. MS 
(ESI): m/z 451.1 ([MH]-, 100). HRMS (ESI) for C22H19N4O7: calculated, 451.1259; found, 451.1250. [𝛼]$%& = -22.5 (c 0.42, MeOH). RP-HPLC purity: 96%. ee = 74% 
  
(S)-methyl 3-(3-(4-hydroxyphenyl)-2-(4-nitro-1H-pyrrole-2-carboxamido) propanamido)benzoate (8d)	
Compound 8d was prepared from 7 and 2,2,2-trichloro-1-(4-nitro-1H-pyrrol-2-yl)ethan-1-one to yield 
orange powder. Yield 40%. mp 140°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.91 (dd, J = 13.8, 10.2 Hz, 
1H, benzyl-CH2), 3.04 (dd, 13.8, 5.0 Hz, 1H, benzyl-CH2), 3.85 (s, 3H, Me-ester-CH3), 4.73 (ddd, J = 
10.2, 8.1, 5.0, 1H, Tyr-α-CH), 6.65 (d, J = 8.4 Hz, 2H, ArH), 7.17 (d, J = 8.4 Hz, 2H, ArH), 7.47 (dd, 
J = 8.0, 8.0 Hz, 1H, ArH), 7.62 (d, J = 1.6 Hz, 1H, ArCH), 7.65 (ddd, J = 8.0, 1.9, 1.3 Hz, 1H, ArH), 
7.88 (ddd, J = 8.0, 1.9, 1.2 Hz, 1H, ArH), 7.91 (d, J = 1.6 Hz, 1H, ArCH), 8.27 (dd, J = 1.9, 1.9 Hz, 
1H, ArH), 8.74 (d, J = 8.1, 1H, amide-NH), 9.2 (bs, 1H, OH), 10.43 (s, 1H, Ar-amide-NH), 12.4 (bs, 
1H, pyrrole-NH) ppm. 13C NMR (DMSO-d6, 100 MHz): δ 36.45, 52.25, 55.81, 106.07, 114.95, 
119.89, 122.88, 123.84, 124.04, 126.49, 127.84, 129.31, 130.12, 136.33, 136.33, 139.23, 155.87, 
159.44, 166.06, 170.69, 172.16 ppm. MS (ESI): m/z 451.1 ([MH]-, 100). HRMS (ESI) for C22H19N4O7: 
calculated, 451.1259; found, 451.1249. [𝛼]$%& = -42.1 (c 0.50, MeOH). RP-HPLC purity: 96%. ee = 
98%. 
General procedure for the preparation of benzoates 8b,e,f, tyrosinate 11 and 4,5-dibromo-1H-
pyrrolecarboxamides 13a-d. 
1H-pyrrole-2-carboxilic acid derivative (1 eq.) or 12 (1 eq.), compound 7 (1 eq.) or 10 or 
corresponding amine, 1-hydroxybenzotriazole (1 eq) and N-methylmorpholine (2 eq.) were dissolved 
in DMF (1mL/mmol) and cooled to 0°C prior to the addition of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (1 eq.). The resulting solution was allowed to warm to room 
temperature during 24 h. The reaction mixture was then concentrated, dissolved in EtOAc and washed 
with 10% water solution of citric acid, 1M NaOH and brine successively. Organic phase was dried 
over Na2SO4, filtered and concentrated.  
(S)-methyl 3-(2-(4,5-dichloro-1H-pyrrole-2-carboxamido)-3-(4-hydroxyphenyl)propanamido) 
benzoate (8b) 
Compound 8b was prepared from 7 and 2,2,2-trichloro-1-(4,5-dichloro-1H-pyrrol-2-yl)ethan-1-one. 
Crude product was purified by flash column chromatography, mobile phase: n-hexane :EtOAc = 2 : 1 
to 1 : 1. Brownish crystals. Yield 45%. mp: 125–127°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.88 (dd, J 
= 13.9, 9.9 Hz, 1H, benzyl-CH2), 3.01 (d, J = 13.9, 1H, benzyl-CH2), 3.85 (s, 3H, Me-ester-CH3), 4.7 
(m, 1H, Tyr-α-CH), 6.64 (d, J = 7.8 Hz, 2H, ArH), 7.04 (d, J = 1.3 Hz, 1H, ArCH), 7.14 (d, J = 7.8 
Hz, 2H, ArH), 7.47 (t, J = 8.1 Hz, 1H ArH), 7.65 (d, J = 8.1 Hz, 1H, ArH), 7.86 (d, J = 8.1 Hz, 1H, 
ArH), 8.26 (s, 1H, ArH), 8.40 (d, J = 7.5 Hz, 1H, amide-NH), 9.19 (s, 1H, Ar-amide-NH), 10.40 (s, 
1H, phenol-OH), 12.68 (d, J = 1.3, 1H, pyrrole-NH) ppm. IR (ATR): ν 3273, 2952, 1705, 1682, 1621, 
1514, 1434, 1299, 1239, 1201, 1173, 752 cm-1. MS (ESI): m/z = 476.1 ([MH]+, 100), 478.1 ([MH+2]+, 
  
64), 480.1 ([MH+4]+, 10). HRMS (ESI) for C22H20N3O5Cl2: calculated, 476.0775; found, 476.0779. [𝛼]$%& = +32.3 (c 1.00, MeOH). RP-HPLC purity: 97%. ee = 98%. 
(S)-methyl 3-(3-(4-hydroxyphenyl)-2-(1H-indole-2-carboxamido)propanamido)benzoate (8e) 
Compound 8e was prepared from 7 and 1H-indole-2-carboxylic acid. The crude product was 
recrystallized from EtOAc/n-hexane mixture to afford pale yellow crystals. Yield: 39%. mp: 127 – 
130°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.99 (dd, J = 13.7, 9.8 Hz, 1H, benzyl-CH2), 3.07 (dd, J = 
13.7, 5.1 Hz, 1H, benzyl-CH2), 3.87 (s, 3H, Me-ester-CH3), 4.79 (ddd, J = 9.8, 7.9, 5.1 Hz, 1H, Tyr-α-
CH), 6.65 (d, J = 8.5 Hz, 2H, ArH), 7.04 (ddd, J = 8.0, 6.9, 0.8 Hz, 1H, ArH), 7.18 (ddd, J = 8.3, 6.9, 
1.1 Hz, 1H, ArH), 7.20 (d, J = 8.5 Hz, 2H, ArH), 7.27 (dd, J = 2.2, 0.9 Hz, 1H, ArH), 7.41 (dd, J = 
8.3, 0.8 Hz, 1H, ArH), 7.49 (dd, J = 8.0, 8.0 Hz, 1H, ArH), 7.65 (dd, J = 8.0, 0.9 Hz, 1H, ArH), 7.67 
(ddd, J = 8.0, 1.6, 1.2 Hz, 1H, ArH), 7.90 (ddd, J = 8.0, 2.2, 1.2 Hz, 1H, ArH), 8.29 (dd, J = 2.2, 1.6 
Hz, 1H, ArH), 8.72 (d, J = 7.9 Hz, 1H, amide-NH), 9.18 (s, 1H, Ar-amide-NH), 10.46 (s, 1H, phenol-
OH), 11.53 (d, J = 2.2 Hz, 1H, indole-NH) ppm. IR (ATR): ν 3283, 2951, 1705, 1624, 1593, 1540, 
1514, 1488, 1439, 1300, 1231, 1202, 1173, 1107, 812, 746 cm-1. MS (ESI): m/z 456.1([MH]-, 100). 
HRMS (ESI) for C26H22N3O5: calculated, 456.1565; found, 456.1555. [𝛼]$%& = +34.2 (c 1.00, MeOH). 
RP-HPLC purity: 96%. ee = 42% 
(S)-methyl 3-(3-(4-hydroxyphenyl)-2-(1H-indazole-3-carboxamido)propanamido) benzoate (8f) 
Compound 8f was prepared from 7 and 1H-indazole-3-carboxylic acid to yield white crystals. mp: 123 
– 124°C. 1H NMR (DMSO-d6, 400 MHz): δ 3.08 (dd, J = 15.4, 6.3, 1H, benzil-CH2), 3.11 (dd, J = 
15.4, 6.3, 1H, benzyl-CH2), 3.85 (s, 3H, Me-ester-CH3), 4.86 (td, J = 8.0, 6.3 Hz, 1H, Tyr-α-CH), 6.64 
(d, J = 8.5 Hz, 2H, ArH), 7.11 (d, J = 8.5 Hz, 2H, ArH), 7.23 (ddd, J = 8.2, 7.0, 0.7 Hz, 1H, ArH), 
7.41 (ddd, J = 8.4, 7.0, 1.0 Hz, 1H, ArH), 7.48 (dd, J = 7.9, 7.9 Hz, 1H, ArH), 7.62 (ddd, J = 8.4, 1.0, 
1.0 Hz), 1H, ArH), 7.66 (ddd, J = 7.9, 1.8, 1.0 Hz, 1H, ArH), 7.87 (ddd, J = 7.9, 2.2, 1.0 Hz, 1H, 
ArH), 8.11 (dd, J = 8.2, 0.7 Hz, 1H, ArH), 8.20 ( d, J = 8.0 Hz, 1H, amide-NH), 8.27 (dd, J = 2.2, 1.8 
Hz, 1H, ArH), 9.21 (s, 1H, Ar-amide-NH), 10.44 (s, 1H, phenol-OH), 13.66 (s, 1H, indazole-NH). IR 
(ATR): ν 3267, 1702, 1639, 1613, 1534, 1514, 1439, 1292, 1234, 1170, 750 cm-1. MS (ESI): m/z 
459.2, ([MH]+, 100). HRMS (ESI) for C25H23N4O5: calculated, 459.1663; found, 459.1664. [𝛼]$%& = -
111.1 (c 0.42, MeOH). RP-HPLC purity: 97%. 
Methyl (4,5-dibromo-1H-pyrrole-2-carbonyl)-L-tyrosinate (11) 
Compound 11[43][2] was prepared from 10[41] and 4,5-dibromo-1H-pyrrole-2-carboxylic acid. The 
crude material was passed through a short pad of silica gel to obtain white solid. Yield 79 %. mp 94 – 
100°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.88 (dd, J = 13.9, 9.9 Hz, 1H, benzyl-CH2), 2.99 (dd, J = 
  
13.9, 5.3 Hz, 1H, benzyl-CH2), 3.61 (s, 3H, CH3), 4.51 (ddd, J = 9.9, 8.0, 5.4 Hz, 1H, Tyr-α-CH), 6.64 
(d, J = 8.5 Hz, 2H, ArH), 7.01 (d, J = 2.4 Hz, 1H, ArH), 7.03 (d, J = 8.5, 2H, ArH), 8.43 (d, J = 8.0 
Hz, 1H, amide-NH), 9.21 (s, 1H, OH), 12.68 (d, J = 2.4 Hz, 1H, pyrrole-NH) ppm. 13C-NMR (DMSO-
d6, 100 MHz): δ 13C NMR (DMSO-d6, 100 MHz): δ 35.73, 53.98, 97.87, 104.92, 113.20, 115.00, 
127.63, 127.95, 129.98, 155.87, 158.75, 173.27 ppm. IR (ATR): ν 3272, 2952, 1724, 1316, 1557, 
1512, 1435, 1209, 1173 cm-1MS (ESI): m/z 546.9 ([MH+2]+, 100), 444.9 ([MH]+, 40.4), 448.9 
([MH+4]+, 48.6). HRMS (ESI) for C15H15N2O4Br2: calculated, 444.9393; found, 444.9396. [𝛼]$%& = -
49.1 (c 1.00, MeOH). RP-HPLC purity: 95%. 
Methyl 1-((4,5-dibromo-1H-pyrrole-2-carbonyl)-L-tyrosyl)piperidine-4-carboxylate (13a) 
Compound 13b was prepared from 12 and methyl piperidine-4-carboxylate. Mobile phase for flash 
column chromatography: DCM : MeOH = 40 : 1. 1H NMR (DMSO-d6, 400 MHz): δ 0.95 – 1.1 (m, 
1H), 1.20 – 1.50 (m, 2H), 1.65 – 1.85 (m, 2H), 2.65 – 2.96 (m, 4H), 3.02 – 3.13 (m, 1H), 3.58 (s, 3H, 
CH3), 3.60 (s, 3H, CH3'), 3.80 – 3.95 (m, 1H), 4.10 – 4.24 (m, 1H), 4.89 – 4.99 (m, 1H, Tyr-α-CH, 
Tyr-α-CH'), 6.61 (d, J = 8.4 Hz, 2H, ArOH, ArOH'), 7.03 (d, J = 8.4 Hz, 2H, ArH), 7.04 (d, J = 8.4 
Hz, 2H, ArH'), 7.06 (d, J = 1.9 Hz, 1H, ArH), 7.07 (d, J = 1.9 Hz, 1H, ArH'), 8.40 (d, J = 8.1 Hz, 1H, 
amide-NH), 8.43 (d, J = 8.1 Hz, 1H, amide-NH'), 9.16 (s, 1H, phenol-OH), 9.17 (phenol-OH'), 12.63 
(d, J = 1.9 Hz, 1H, pyrrole-NH), 12.66 (d, J = 1.9 Hz, 1H, pyrrole-NH') ppm. IR (ATR): ν 3154, 2951, 
1724, 1610, 1544. 1513, 1448, 1378, 1206, 1172, 1037 cm-1. MS (ESI): m/z 556.0 ([MH+2]-, 100), 
554.0 ([MH]-, 51.4), 558.0 ([MH+4]-, 48.6). HRMS (ESI) for C21H22N3O5Br2: calculated, 553.9932; 
found, 553.9920. [𝛼]$%& = -10.1 (c 1.00, MeOH). RP-HPLC purity: 98%. 
Dimethyl (4,5-dibromo-1H-pyrrole-2-carbonyl)-L-tyrosyl-L-aspartate (13b) 
Compound 13c was prepared from 12 and dimethyl L-aspartate. Mobile phase for flash column 
chromatography: DCM : MeOH = 40 : 1 to 20 : 1. Yield: 75 %, off-white solid. mp: 98 – 101°C. 1H-
NMR (DMSO-d6, 400 MHz): δ 2.72 (dd, J = 16.4, 7.1 Hz, 1H, Asp-β-CH2), 2.73 (dd, J = 13.8, 10.7 
Hz, 1H, benzyl-CH2), 2.83 (dd, J = 16.4, 6.2 Hz, 1H Asp-β-CH2), 2.95 (dd, J = 13.8, 3.8 Hz, 1H, 
benzyl-CH2), 3.60 (s, 3H, CH3), 3.61 (s, 3H, CH3), 4.57 (ddd, J = 10.7, 8.6, 3.8 Hz, 1H, Tyr-α-CH), 
4.66 (ddd, J = 7.9, 6.2, 7.1 Hz, 1H, Asp-α-CH), 6.61 (d, J = 8.5 Hz, 2H, ArH), 7.01 (d, J = 2.7 Hz, 1H, 
ArH), 7.08 (d, J = 8.5 Hz, 2H, ArH), 8.20 (d, J = 8.6 Hz, 1H, Asp-NH), 8.58 (d, J = 7.9 Hz, 1H, Tyr-
NH), 9.15 (s, 1H, OH), 12.62 (d, J = 2.7 Hz, 1H, pyrrole-NH) ppm. IR (ATR): ν 3279, 2952, 1732, 
1629, 1543, 1504, 1436, 1372, 1217, 1172 cm-1. MS (ESI): m/z 574.0 ([MH+2]-, 100), 572.0 ([MH]-, 
51.4), 576.0 ([MH+4]-, 48.6). HRMS for C20H20N3O7Br2: calculated, 571.9673; found, 571.9662.  
  
Dimethyl (4,5-dibromo-1H-pyrrole-2-carbonyl)-L-tyrosyl-L-glutamate (13c) 
Compound 13d was prepared from 12 and dimethyl L-aspartate. Mobile phase for flash column 
chromatography: DCM : MeOH = 20 : 1. Yield: 80 %, off-white solid. mp: 96 – 98°C. 1H NMR 
(DMSO-d6, 400 MHz): δ 1.82 (ddt, J = 13.7, 9.2, 7.5 Hz, 1H, Glu-β-CH2), 1.98 (dtd, J = 13.7, 7.5, 5.5 
Hz, 1H, Glu-β-CH2), 2.30 (t, J = 7.5 Hz, 2H, Glu-γ-CH2), 2.75 (dd, J = 13.8, 10.4 Hz, 1H, benzyl-
CH2), 2.91 (dd, J = 13.8, 4.5 Hz, 1H, benzyl-CH2), 3.58 (s, 3H, CH3), 3.62 (s, 3H, CH3), 4.30 (ddd, J = 
9.2, 7.8, 5.5 Hz, 1H, Glu-α-CH), 4.63 (ddd, J = 10.4, 8.6, 4.5 Hz, 1H, Tyr-α-CH), 6.61 (d, J = 8.4 Hz, 
2H, ArH), 7.03 (d, J = 2.8 Hz, 1H ArH), 7.08 (d, J = 8.4Hz, 2H, ArH), 8.19 (d, J = 8.6 Hz, 1H, Tyr-
NH), 8.54 (d, J = 7.8 Hz, Glu-NH), 9.14 (s, 1H, OH), 12.63 (d, J = 2.8 Hz, 1H, pyrrole-NH). 13C NMR 
(DMSO-d6, 100 MHz): δ 26.14, 29.43, 36.99, 50.97, 51.40, 51.97, 54.30, 97.82, 104.66, 113.33, 
114.82, 127.69, 127.95, 130.04, 155.76, 158.48, 171.62, 171.97, 172.56. IR (ATR): ν 3288, 2952, 
1725, 1630, 1557, 1513, 1436, 1415, 1326, 1209, 1172, 973, 825, 756 cm-1. MS (ESI): m/z 590.0 
([MH+2]+, 100), 588.0 ([MH]+, 51.4), 592.0 ([MH+4]+, 48.6). HRMS (ESI) for C21H24N3O7Br2: 
calculated, 587.9976; found, 587.9976. [𝛼]$%& = -36.7 (c 1.00, MeOH). RP-HPLC purity: 96%. ee = 
90% 
Methyl (S)-4-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)-3-(4-hydroxyphenyl)propanamido)me-
thyl)benzoate (13d) 
Compound 13d was prepared from 12 and 4-(methoxycarbonyl)phenyl)methanaminium chloride. 
Mobile phase for flash column chromatography: DCM : MeOH = 40:1 to 20:1. Yield: 45%, white 
crystals. mp: 135°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.81 (dd, J = 13.8, 9.9 Hz, 1H, Tyr-benzyl-
CH2), 2.98 (dd, J = 13.8, 5.1 Hz, 1H, Tyr-benzyl-CH2), 3.84 (s, 3H, CH3), 4.32 (dd, J = 16.4, 6.1 Hz, 
1H, NH-benzyl-CH2), 4.38 (dd, J = 16.4, 6.1 Hz, 1H, NH-benzil-CH2), 4.58 (ddd, J = 9.9, 8.4, 5.1 Hz, 
1H, Tyr-α-CH), 6.63 (d, J = 8.5 Hz, 2H, ArH), 7.04 (d, J = 2.6 Hz, 1H, ArH), 7.08 (d, J = 8.5 Hz, 2H, 
ArH), 7.29 (d, J = 8.3 Hz, 2H, ArH), 7.88 (d, J = 8.3 Hz, 2H, benzoate-3,5-H), 8.27 (d, J = 8.4 Hz, 1H, 
amide-NH(at pyrrole), 8.65 (t, J = 6.1 Hz, 1H, amide-NH at aminomethylbenzoate), 9.19 (s, 1H, 
phenol-OH), 12.64 (d, J = 2.6 Hz, pyrrole-NH) ppm. 13C NMR (DMSO-d6, 100 MHz): δ 36.68, 41.86, 
52.11, 54.91, 97.85, 104.711, 113.41, 114.93, 127.17, 127.76, 128.04, 128.11, 129.16, 130.09, 145.08, 
155.81, 158.68, 166.12, 171.53 ppm. IR (ATR): ν 3282, 2950, 1702, 1613, 1557, 1513, 1434, 1415, 
1281, 1224, 1178, 1107, 1019, 972, 832, 752, 705 cm-1. MS (ESI): m/z 578.0 ([MH+2]-, 100), 576.0 
([MH]-, 51.4), 580.0 ([MH+4]-, 48.6). HRMS (ESI) for C23H20N3O5Br2: calculated, 575.9775; found, 
575.9770. [𝛼]$%& = -8.96 (c 1.00, MeOH). RP-HPLC purity: 100%. ee = 91% 
 
  
General procedure for the preparation of the target compounds 9a-f, 12 and 14a-e 
Compound 8a-f, 12 or 14a-e (1 eq.) was dissolved in a mixture of THF (1 mL/mmol) and LiOH 
solution (5 eq., 1M solution), and stirred overnight at room temperature. EtOAc and 1M NaOH were 
then added, layers were separated and organic phase washed again with 1M NaOH. To the combined 
water phases concentrated hydrochloric acid was added until pH = 1 was reached. The compound was 
then extracted to EtOAc, combined organic phases were washed with brine, dried over Na2SO4, 
filtered and concentrated. The crude residue is purified by flash column chromatography or 
crystallized. 
(S)-3-(2-(4,5-dibromo-1H-pyrrole-2-carboxamido)-3-(4-hydroxyphenyl) propanamido)benzoic acid 
(9a) 
Compound 9a was prepared from 8a and the oily residue obtained was purified by flash column 
chromatography, mobile phase: n-hexane:EtOAc:AcOH = 1:1:0.1 to yield brown crystals. Yield 95%. 
mp: 127 – 132°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.88 (dd, J = 13.7 Hz, 10.3 Hz, 1H, benzyl-H), 
3.01 (dd, J = 13.7, 4.5 Hz, 1H, benzyl-H), 4.69 (ddd, J = 10.3, 8.0, 4.5 Hz, 1H, Tyr-α-CH), 6.64 (d, J = 
8.4 Hz, 2H, ArH), 7.07 (s, 1H, ArH), 7.14 (d, J = 8.4 Hz, 2H, ArH), 7.43 (dd, J = 7.9, 7.9 Hz, 1H, 
ArH), 7.63 (d, J = 7.9 Hz, 1H, ArH), 7.84 (d, J = 7.9 Hz, 1H, ArH), 8.22 (s, 1H, ArH), 8.37 (d, J = 8.0 
Hz, 1H, amide-NH), 9.19 (s, 1H, Ar-amide-NH), 10.36 (s, 1H, phenol-OH), 12.64 (s, 1H, pyrrole-
NH), 13.0 (bs, 1H, COOH) ppm. IR (ATR): ν 3144, 2359, 1683, 1612, 1554, 1513, 1437, 1392, 1301, 
1232, 1106, 974, 809, 752 cm-1. MS (ESI): m/z 548.0 ([MH]-, 51), 550.0 ([MH+2]-, 100), 552.0 
([MH+4]-, 49). HRMS for C21H16N3O5Br2: calculated, 547.9462; found, 547.9469. [𝛼]$%& = +27.0 (c 
1.00, MeOH). RP-HPLC purity: 95%. ee = 90%.  
(S)-3-(2-(4,5-dichloro-1H-pyrrole-2-carboxamido)-3-(4-hydroxyphenyl)propan amido)benzoic acid 
(9b) 
Compound 9b was prepared from 8b to yield brown crystals. mp: 127–132°C. 1H NMR (DMSO-d6, 
400 MHz): δ 2.89 (dd,  J = 13.8, 10.1 Hz, 1H, benzyl-H), 3.02 (dd, 13.8, 4.8 Hz, 1H, benzyl-H), 4.70 
(ddd, J = 10.1, 7.9, 4.8 Hz, 1H, Tyr-α-CH), 6.65 (d, J = 8.4 Hz, 2H, ArH), 7.05 (s, 1H, ArH), 7.15 (d J 
= 8.4 Hz, 2H, ArH), 7.44 (dd, J = 8.0, 7.8 Hz, 1H, ArH), 7.64 (ddd, J = 7.8, 1.6, 1.1 Hz, 1H, ArH), 
7.85 (ddd, J = 8.0, 2.3, 1.0 Hz, 1H, ArH), 8.23 (dd, J = 2.3, 1.6 Hz, 1H, ArH), 8.41 (d J = 7.9 Hz, 1H, 
amide-NH), 9.20 (s, 1H, Ar-amide-NH), 10.37 (s, 1H, phenol-OH), 12.70 (s, 1H, pyrrole-NH), 12.9 
(bs, COOH) ppm. IR (ATR): ν 3270, 1677, 1612, 1599, 1560, 1513, 1436, 1229, 1104, 1019, 812, 754 
cm-1. MS (ESI): m/z 460.1 ([MH]-, 100), 462.1 ([MH+2]-, 64), 464.1 ([MH+4]-, 10). HRMS for 
C21H16N3O5Cl2: calculated, 460.0472; found, 460.0472. [𝛼]$%& = +29.2 (c 1.00, MeOH). ee= 97% 
  
(S)-3-(3-(4-hydroxyphenyl)-2-(5-nitro-1H-pyrrole-2-carboxamido)propanamido) benzoic acid (9c) 
Compound 9c was prepared from 8c to yield brown crystals. Yield 96%. mp 125 – 134°C. 1H NMR 
(DMSO-d6, 400 MHz): δ 2.91 (m, 1H, benzyl-CH2), 3.07 (m, 1H, benzyl-CH2), 4.80 (m, 1H, Tyr-α-
CH), 6.66 (d, J = 8.1 Hz, 2H, ArH), 6.93 (s, 1H, ArH), 7.15 (m, 3H, ArH in pyrrole CH), 7.65 (dd, J = 
7.6, 7.6 Hz, 1H, ArH), 7.65 (d, J = 7.6 Hz, 1H, ArH), 7.85 (d, J = 7.6 Hz, 1H, ArH), 8.24 (s, 1H), 8.86 
(d, J = 6.7 Hz, pyrrole-CONH), 9.23 (s, 1H), 10.45 (s, 1H, phenol-OH), 12.6-13.3 (bs, 1H, COOH), 
13.53 (s, 1H, pyrrole-NH) ppm. IR (ATR): ν 3276, 3128, 1696, 1638, 1592, 1556, 1514, 1446, 1367, 
1288, 1231, 1174, 1106, 1046, 807, 754 cm-1.  MS (ESI): m/z 437.1 ([MH]-, 100). HRMS (ESI) for 
C21H17N4O7: calculated, 437.1103; found, 437.1094.	[𝛼]$%& = +11.7 (c 1.00, MeOH). RP-HPLC 
purity:97%. ee = 74% 
(S)-3-(3-(4-hydroxyphenyl)-2-(4-nitro-1H-pyrrole-2-carboxamido)propanamido) benzoic acid (9d) 
Compound 9d was prepared from 8d to yield brown crystals. Yield 95%. mp: 163–165°C. 1H NMR 
(MeOH-d4, 400 MHz): δ 3.06 (dd, J = 13.7, 8.3 Hz, 1H, benzyl-H), 3.20 (dd, J = 13.7, 7.1 Hz, 1H, 
benzyl-H), 4.87 (dd,  J = 8.3, 7.1 Hz, 1H, Tyr-α-CH), 6.71 (d, J = 8.5 Hz, 2H, ArH), 6.91 (d, J = 4.3 
Hz, 1H, ArH), 7.07 (d, J = 4.3 Hz, 1H, ArH), 7.15 (d, J = 8.5 Hz, 2H, ArH), 7.42 (dd, J = 8.0, 8.0 Hz, 
1H, ArH), 7.73 – 7.77 (m, 2H, ArH), 8.17 (t, J = 2.0 Hz, ArH) ppm. 13C NMR (DMSO-d6, 100 MHz): 
δ 38.51, 57.61, 111.37, 113.42, 116.41, 122.76, 125.89, 126.69, 128.84, 130.04, 130.66, 131.51, 
132.74, 139.78, 140.68, 157.53, 161.43, 169.57, 172.43 ppm. IR (ATR): ν 3267, 3137, 1693, 1671, 
1611, 1593, 1531, 1514, 1446, 1414, 1370, 1312, 1259, 1205, 1174, 1105, 889, 839, 811, 749 cm-1. 
MS (ESI): m/z 437.1 ([MH]-, 100). HRMS (ESI) for C21H17N4O7: calculated, 437.1103; found, 
437.1093.	[𝛼]$%& = +49.7 (c 1.00, MeOH). RP-HPLC purity: 95%. ee = 98%. 
(S)-3-(3-(4-hydroxyphenyl)-2-(1H-indole-2-carboxamido)propanamido)benzoic acid (9e) 
Compound 9e was prepared from compound 8e. The crude product was purified by crystallization 
from the mixture of n-hexane and EtOAc to get white crystals. Yield 97%. mp: 146 – 149°C. 1H NMR 
(DMSO-d6, 400 MHz): δ 2.97 (dd, J = 13.6, 10.0 Hz, 1H, benzyl-CH2), 3.06 (dd, J = 13.6, 4.9 Hz, 1H, 
benzyl-CH2), 4.78 (ddd, J = 10.0, 8.2, 4.9 Hz, 1H, Tyr-α-CH), 6.64 (d, J = 8.4 Hz, ArH), 7.03 (ddd, J 
= 8.0, 7.0, 0.9 Hz, 1H, indole-5-H), 7.17 (ddd, J = 8.3, 7.0, 1.1 Hz, 1H, indole-6-H), 7.19 (d, J = 8.4 
Hz, 2H, ArH), 7.25 (dd, J = 2.1, 0.8 Hz, 1H, indole-3-H), 7.40 (dd, J = 8.3, 0.9 Hz, 1H, ArH), 7.44 
(dd, J = 8.0, 8.0 Hz), 7.61-7.65 (m, 2H, ArH), 7.85 (ddd, J = 8.0, 1.9, 1.0 Hz, 1H, ArH), 8.24 (dd, J = 
1.9, 1.9 Hz, 1H, ArH), 8.70 (d, J = 8.2 Hz, 1H, pyrrole-CONH), 9.23 (s, 1H, Ar-amide-NH), 10.41 (s, 
1H, phenol-OH), 11.5 (d, J = 2.1 Hz, 1H, pyrrole-NH), 16.5 (bs, 1H, COOH) ppm. IR (ATR): ν 3236, 
1707, 1687, 1635, 1618, 1540, 1514, 1485, 1373, 1300, 1251, 1198, 1168, 1115, 1047, 809, 757, 679, 
  
649 cm-1. MS (ESI): m/z 442.1 ([MH]-, 100). HRMS (ESI) for C25H20N3O5: calculated, 442.1408; 
found, 442.1400. [𝛼]$%& = +29.1 (c 1.00, MeOH). RP-HPLC purity: 99%. ee =42%. 
3-(3-(4-hydroxyphenyl)-2-(1H-indazole-3-carboxamido)propanamido)benzoic acid (9f) 
Compound 9f was prepared from compound 8f. The crude material was purified using flash column 
chromatography and mobile phase n-hexane : EtOAc : AcOH = 1:5:0.05 to yield white crystals. Yield 
95%. mp: 125–130°C. 1H NMR (DMSO-d6, 400 MHz): δ 3.06-3.11 (m, 2H, benzyl-CH2), 4.85 (m, 
1H, Tyr-α-CH), 6.63 (d, J = 8.5 Hz, 2H, ArH), 7.11 (d, J = 8.5 Hz, 2H, ArH), 7.23 (ddd, J = 8.1, 7.0, 
0.7 Hz, 1H, ArH), 7.41 (ddd, J = 8.3, 7.0, 1.1 Hz, 1H, ArH), 7.44 (dd, J = 7.9, 7.9 Hz, 1H, ArH), 7.62 
(ddd, J = 8.3, 0.7, 0.7 Hz, 1H, ArH), 7.63 (ddd, J = 7.9, 1.7, 1.0 Hz, 1H, ArH), 7.84 (ddd, J = 7.9, 2.1, 
1.0 Hz, 1H, ArH), 8.10 (d, J = 8.1 Hz, 1H), 8.18 (d, J = 8.1 Hz, 1H), 8.22 (dd, J = 2.1, 1.7 Hz, 1H, 
ArH). IR (ATR): ν 3261, 1642, 1613, 1593, 1534, 1514, 1444, 1234, 1169, 749 cm-1. MS (ESI) m/z = 
445.1 ([MH]+, 100). HRMS (ESI) for C24H21N4O5: calculated, 445.1506; found, 445.1499. RP-HPLC 
purity: 96%. ee = 0% 
4,5-dibromo-1H-pyrrole-2-carbonyl-L-tyrosine (12) 
Compound 12 was prepared from 11 to yield brownish crystals. Yield 95%. mp: 113 – 117°C. 1H 
NMR (DMSO-d6, 400 MHz): δ 2.85 (dd, J = 13.8, 10.3 Hz, 1H, benzyl-CH2), 3.03 (dd, J = 13.8, 4.3 
Hz, 1H, benzyl-CH2), 4.47 (ddd, J = 10.3, 8.3, 4.3 Hz, 1H, Tyr-α-CH), 6.64 (d, J=8.4 Hz, 2H, ArH), 
7.02 (s, 1H, ArH), 7.06 (d, J = 8.4 Hz, 2H, ArH), 8.3 (d, J = 8.3 Hz, 1H, amide-NH), 9.20 (s, 1H, 
phenol-OH), 12.67 (s, 1H, pyrrole-NH), 12.7 (bs, 1H, COOH) ppm. 13C NMR (DMSO-d6, 100 MHz): 
δ 35.71, 53.96, 97.85, 104.90, 113.18, 114.99, 127.60, 127.93, 129.95, 155.85, 158.72, 173.25 ppm. 
IR (ATR): ν 3174, 2924, 1716, 1612, 1557, 1413, 1212 cm-1. MS (ESI) m/z = 432.9 ([MH+2]+, 100), 
430.9 ([MH]+, 40.4), 434.9 ([MH+4]+, 48.6). HRMS (ESI) for C14H13N2O4Br2: calculated, 430.9237; 
found, 430.9240. [𝛼]$%& = -37.5 (c 1.00, MeOH). RP-HPLC purity: 96%.  
1-((4,5-dibromo-1H-pyrrole-2-carbonyl)-L-tyrosyl)piperidine-4-carboxylic acid (14a) 
Compound 14a was prepared from compound 13a. After neutralization of water phase, white 
precipitate forms, which is filtered and dried in vacuo for 1 h. mp: 158 – 161°C. 1H NMR (DMSO-d6, 
400 MHz): δ 1.10 – 1.50 (m, 2H), 1.68 – 1.84 (m, 2H), 2.60 – 3.16 (m, 5H), 3.80 – 3.94 (m, 1H), 4.07 
– 4.29 (m, 1H), 4.96 (m, 1H, Tyr-α-CH), 6.63 (d, J = 8.4 Hz, 2H, ArH), 7.06 (m, 3H, ArH), 8.41 (d, J 
= 8.3 Hz, amide-NH), 8.45 (d, J = 8.3 Hz, amide-NH'), 9.18 (s, 1H, phenol-OH), 9.19 (s, 1H, phenol-
OH'), 12.25 (s, 1H, COOH), 12.65 (s, 1H, pyrrole-NH), 12.68 (s, 1H, pyrrole-NH') ppm. IR (ATR): ν 
3150, 2957, 1706, 1609, 1546, 1448, 1378, 1208, 1173 cm-1.MS (ESI): m/z 542.0 ([MH+2]-, 100), 
  
540.0 ([MH]-, 51.4), 544.0 ([MH+4]-, 48.6). HRMS (ESI) for C20H20N3O5Br2: calculated, 539.9775; 
found, 539.9764. [𝛼]$%& = 97.6 (c 0.21, DMSO). RP-HPLC purity: 95%. 
(4,5-dibromo-1H-pyrrole-2-carbonyl)-L-tyrosyl-L-aspartic acid (14b) 
Compound 14b was prepared from compound 13b. After neutralization of water phase, white 
precipitate forms, which is filtered and dried in vacuo for 1 h. mp: 230 – 233 °C. 1H NMR (DMSO-d6, 
400 MHz): δ 2.6 (dd, J = 16.8, 6.9 Hz, 1H, Asp-β-CH2), 2.7 (m, 2H, Asp-β-CH2 and benzyl-CH2), 
2.98 (dd, J = 14.0, 3.4 Hz, benzyl-CH2), 4.6 (m, 2H, Tyr-α-CH in Asp-α-CH), 6.60 (d, J = 8.5 Hz, 2H, 
ArH), 7.00 (d, J = 2.7 Hz, 1H, ArH), 7.08 (d, J = 8.5 Hz, 2H, ArH), 8.19 (d, J = 8.7 Hz, 1H, Glu-NH), 
8.43 (d, J = 8.0 Hz, Tyr-NH), 9.14 (s, 1H, OH), 12.1 – 12.6 (bs, 2H, COOH), 12.61 (d, J = 2.7 Hz, 1H, 
pyrrole-NH) ppm. 13C NMR (DMSO-d6, 100 MHz): δ 38.08, 38.31, 51.32, 56.42, 100.10, 106.49, 
115.04, 116.33, 128.52, 129.51, 131.48, 157.29, 161.38, 173.43, 175.41, 175.50 ppm. IR (ATR): ν 
3404, 3288, 3066, 2969, 1718, 1690, 1674, 1625, 1542, 1505, 1279 cm-1. MS (ESI): m/z 545.9 
([MH+2]-, 100), 543.9 ([MH]-, 51.4), 547.9 ([MH+4]-, 48.6). HRMS (ESI) for C18H16N3O7Br2: 
calculated, 543.9360; found, 543.9343. RP-HPLC purity: diastereomers: 84.4% and 13.9% .  
(4,5-dibromo-1H-pyrrole-2-carbonyl)-L-tyrosyl-L-glutamic acid (14c) 
Compound 14c was prepared from compound 13c. After neutralization of water phase, white 
precipitate forms, which is filtered and dried in vacuo for 1 h. mp: 132 – 135°C. 1H NMR (DMSO-d6, 
400 MHz): δ 1.77 (dtd, J  = 13.9, 7.6, 8.1 Hz, 1H, Glu-β-CH2), 1.97 (dtd, J 13.9, 7.6, 5.2 Hz, 1H, Glu-
β-CH2), 2.23 (t, J = 7.6 Hz, 2H, Glu-γ-CH), 2.74 (dd, J = 13.8, 10.8 Hz, 1H, benzyl-CH2), 2.92 (dd, J 
= 13.8, 4.2 Hz, 1H, benzyl-CH2), 4.24 (ddd, J = 8.7, 8.1, 5.2 Hz, 1H, Glu-α-CH), 4.65 (ddd, 10.8, 8.0, 
4.2 Hz, 1H, Tyr-α-CH), 6.60 (d, J = 8.4 Hz, 2H, ArH), 7.02 (d, J = 2.6 Hz, 1H, ArH), 7.09 (d, J = 8.4 
Hz, 2H, ArH), 8.17 (d, J = 8.7 Hz, 1H, Glu-NH), 8.4 (d, J = 8.0 Hz, 1H, Tyr-NH), 9.14 (s, 1H, OH), 
12.0-12.6 (bs, 2H, COOH), 12.62 (d, J = 2.6 Hz, pyrrole-NH) ppm. 13C NMR (DMSO-d6, 100 MHz): 
δ 26.48, 29.89, 37.09, 51.08, 54.33, 97.79, 104.61, 113.28, 114.81, 127.73, 128.10, 130.06, 155.71, 
158.45, 171.53, 173.13, 173.69 ppm. IR (ATR): ν 3420, 3356, 3295, 3105, 2962, 1725, 1660, 1555, 
1515, 1609, 1224, 1167, 1113, 984, 896, 814 cm-1. MS (ESI): m/z 559.9 ([MH+2]-, 100), 558.0 ([MH]-
, 51.4), 561.9 ([MH+4]-, 48.6). HRMS (ESI) for C19H18N3O7Br2: calculated, 557.9517; found, 
557.9500.	[𝛼]$%& = -27.6 (c 1.00, MeOH). RP-HPLC purity: 98%.  
(S)-4-((2-(4,5-dibromo-1H-pyrrole-2-carboxamido)-3-(4-hydroxyphenyl)propanamido)methyl)benzoic 
acid (14d) 
Compound 14d was prepared from compound 13d. After neutralization of water phase, white 
precipitate forms, which is filtered and dried in vacuo for 1 h. mp: 232 – 235°C. 1H NMR (DMSO-d6, 
  
400 MHz): δ 2.82 (dd, J = 13.7, 10.1 Hz, 1H, Tyr-benzyl-CH2), 2.99 (dd, J = 13.7, 5.2 Hz, 1H, benzyl-
CH2), 4.33 (dd, J = 16.1, 5.9 Hz, 1H, NH-benzyl-CH2), 4.38 (dd, J = 16.1, 5.9 Hz, 1H, NH-benzyl-
CH2), 4.6 (ddd, J = 10.1, 8.2, 5.2 Hz, 1H, Tyr-α-CH), 6.64 (d, J = 8.5 Hz, 2H, ArH), 7.05 (s, 1H, 
ArH), 7.09 (d, J = 8.5 Hz, 2H, ArH), 7.27 (d, J = 8.3 Hz, 2H, ArH), 7.87 (d, J = 8.3 Hz, ArH), 8.28 (d, 
J = 8.2 Hz, 1H, amide-NH at pyrrole), 8.65 (t, J = 5.9 Hz, 1H, amide-NH at aminomethylbenzoate), 
9.20 (s, 1H, OH), 12.66 (s, 1H, pyrrole-NH), 12.9 (bs, 1H, COOH) ppm. 13C NMR (DMSO-d6, 100 
MHz): δ 36.70, 41.88, 54.91, 97.87, 104.72, 113.41, 114.97, 127.00, 127.76, 128.11, 129.17, 129.30, 
130.08, 144.55, 155.81, 158.67, 167.20, 171.49 ppm. IR (ATR): ν 3293, 3115, 2947, 1700, 1626, 
1590, 1553, 1513, 1449, 1405, 1382, 1243, 1172, 751 cm-1. MS (ESI): m/z 564.0 ([MH+2]-, 100), 
562.0 ([MH]-, 51.4), 566.0 ([MH+4]-, 48.6). HRMS (ESI) for C22H18N3O5Br2: calculated, 561.9619; 
found, 561.9613. [𝛼]$%& = -8.3 (c 1.00, MeOH). RP-HPLC purity: 98%. ee = 93% 
(S)-5-(2-(4,5-dibromo-1H-pyrrole-2-carboxamido)-3-(4-hydroxyphenyl)propanamido)-2-
hydroxybenzoic acid (14e) 
Compound 14e was prepared from compound 13e. After neutralization of water phase, white 
precipitate forms, which is filtered and dried in vacuo for 1 h. mp: 246 – 250°C. 1H NMR (DMSO-d6, 
400 MHz): δ 2.87 (dd, J = 13.8, 9.9 Hz, 1H, benzyl-CH2), 3.00 (dd, J  = 13.8, 4.8 Hz, 1H, benzyl-
CH2), 4.65 (ddd, J = 9.9, 8.2, 4.8 Hz, 1H, Tyr-α-CH), 6.64 (d, J = 8.4 Hz, 2H, ArH), 6.93 (d, J = 9.0 
Hz, 1H, ArH), 7.07 (d, J = 2.7 Hz, 1H, ArH), 7.13 (d, J = 8.4 Hz, 2H, ArH), 7.68 (dd, J = 9.0, 2,7 Hz, 
1H, ArH), 8.09 (d, J = 2.7 Hz, 1H, ArH), 8.35 (d, J = 8.2 Hz, 1H, amide-NH), 9.19 (s, 1H, Ar-amide 
NH), 10.13 (s, 1H, Tyr-OH), 11.0 (bs, 1H, salicyl-OH), 12.64 (d,  J = 2.7 Hz, 1H, pyrrole-NH), 14.0 
(bs, 1H, COOH) ppm. 13C NMR (DMSO-d6, 100 MHz): δ 36.65, 55.51, 97.88, 104.82, 112.43, 113.47, 
114.92, 117.22, 120.76, 127.65, 127.65, 130.11, 130.58, 155.82, 157.18, 158.77, 170.15, 171.68 ppm. 
IR (ATR): ν 3173, 3122, 3073, 2957, 1662, 1595, 1550, 1450, 1284, 1226, 1172, 834, 673 cm-1. MS 
(ESI): m/z 565.9 ([MH+2]-, 100), 563.9 ([MH]-, 51.4), 567.9 ([MH+4]-, 48.6), [M-H]-. HRMS (ESI) 
for C21H16N3O6Br2: calculated, 563.9411; found, 563.9406. [𝛼]$%& = +12.9 (c 1.00, MeOH). RP-HPLC 
purity: 96%.  
General procedure for the synthesis of 13e-h.  
Compound 12 (1 eq.), aromatic amine (1.1 eq.), 1-hydrohybenzotriazole (1 eq.), DMAP (1 eq.) and N-
methylmorpholine (4 eq.) were dissolved in DMF (10 mL/mmol) and cooled to 0°C prior to addition 
of EDC (1.1 eq.). The reaction mixture was stirred for 15 min at 0°C and overnight at 60°C, 
concentrated and the residue dissolved in EtOAc. The resulting solution was then washed with 10% 
water solution of citric acid, concentrated solution of NaHCO3 and brine successively. Organic phase 
was dried over Na2SO4, filtered and concentrated. The crude residue was purified by flash column 
chromatography 
  
Methyl 5-(2-(4,5-dibromo-1H-pyrrole-2-carboxamido)-3-(4-hydroxyphenyl)propanamido)-2-
hydroxybenzoate (13e) 
Compound 13e was prepared from 12 and methyl 5-aminosalicylate. Mobile phase: DCM : MeOH = 
40:1 to 20:1. Recrystalization from a mixture of DCM and MeOH. Pale yellow crystals. Yield 53%. 
mp: 217 – 220°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.86 (dd, J = 13.8, 9.8 Hz, 1H, benzyl-CH2), 2.99 
(dd, J = 13.8, 5.1 Hz, 1H, benzyl-CH2), 3.89 (s, 3H, CH3), 4.63 (ddd, J = 9.8, 8.2, 5.1 Hz, 1H, Tyr-α-
CH), 6.63 (d, J = 8.5 Hz, 2H, ArH), 6.95 (d, J = 9.0 Hz, 1H, ArH), 7.06 (d, J = 2.8 Hz, 1H, ArH), 7.12 
(d, J = 8.5 Hz, 2H, ArH), 7.66 (dd, J = 9.0, 2.7 Hz, 1H, ArH), 8.09 (d, J = 2.7, 1H, ArH), 8.33 (d, J = 
8.2, 1H, amide-NH), 9.18 (s, 1H, Ar-amide-NH), 10.13 (s, 1H, salicyl-OH), 10.27 (s, 1H, Tyr-OH), 
12.63 (d, J = 2.8, 1H, pyrrole-NH) ppm. 13C NMR (DMSO-d6, 100 MHz): δ 36.59, 52.52, 55.48, 
97.86, 104.81, 112.47, 113.44, 114.89, 117.57, 120.45, 127.57, 127.61, 130.07, 130.72, 155.79, 
156.03, 158.75, 168.92, 170.13 ppm. IR (ATR): ν 3381, 3259, 3149, 1669, 1627, 1560, 1512, 1492, 
1199, 1167, 1083, 973, 826, 793 cm-1. MS (ESI): m/z 580.0 ([MH+2]-, 100), 578.0 ([MH]-, 51.4), 
582.0 ([MH+4]-, 48.6). HRMS (ESI) for C22H18N3O6Br2: calculated, 577.9568; found, 577.9562. RP-
HPLC purity: 97%. ee = 0% 
4,5-dibromo-N-(3-(4-hydroxyphenyl)-1-((3-hydroxyphenyl)amino)-1-oxopropan-2-yl)-1H-pyrrole-2-
carboxamide (13f) 
Compound 13g was prepared from 12 and 3-aminophenol. The crude product after extraction was 
dissolved in MeOH and the yellow impurity filtered off. Mother liquor was concentrated and purified 
by flash column chromatography, mobile phase: DCM:MeOH = 20:1. Yield: 14%. White crystals. 
Mp: 145 – 147°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.84 (dd, J = 13.8, 10.3 Hz, 1H, benzyl-CH2), 
2.96 (dd, J = 13.8, 4.6 Hz, 1H, benzyl-CH2), 4.69 (ddd, J = 10.3, 8.4, 4.6 Hz, 1H, Tyr-α-CH), 6.45 
(ddd, J = 8.0, 2.3, 0.9 Hz, 1H, ArH), 6.63 (d, J = 8.5, 2H, ArH), 6.96 (ddd, J = 8.0, 2.1, 0.9 Hz, 1H, 
ArH), 7.06 (d, J = 2.6 Hz, 1H, ArH), 7.07 (dd, J = 8.0, 8.0 Hz, 1H, ArH), 7.13 (d, J = 8.5 Hz, 2H, 
ArH), 7.17 (dd, J = 2.3, 2.1 Hz, 1H, ArH), 8.33 (d, J = 8.2 Hz, 1H, amide-NH), 9.18 (s, 1H, OH), 9.39 
(s, 1H, OH), 10.04 (s, 1H), 12.63 (d, J = 2.6 Hz, 1H, pyrrole-NH) ppm. 13C NMR (DMSO-d6, 100 
MHz): δ 38.59, 57.20, 100.12, 106.47, 108.76, 112.50, 115.15, 116.29, 128.38, 128.95, 130.51, 
131.44, 140.39, 157.33, 158.87, 161.29, 172.20 ppm. MS (ESI): m/z = 521.9 ([MH+2]-, 100), 519.9 
([MH]-, 51.4), 523.9 ([MH+4]-, 48.6). HRMS (ESI) for C20H16N3O4Br2: calculated, 519.9513; found, 
519.9508. RP-HPLC purity: 96%. ee= 0%  
  
4,5-dibromo-N-(3-(4-hydroxyphenyl)-1-oxo-1-(phenylamino)propan-2-yl)-1H-pyrrole-2-carboxamide 
(13g) 
Compound 13h was prepared from 12 and aniline. The crude product after extraction was dissolved in 
MeOH and the yellow impurity filtered off. Mother liquor was concentrated and purified by flash 
column chromatography, mobile phase: DCM:MeOH = 40:1. Yield: 14%, pale yellow solid. mp: 
130°C. 1H NMR (DMSO-d6, 400 MHz): δ 2.86 (dd, J = 13.8, 10.2 Hz, 1H, benzyl-CH2), 2.98 (dd, J = 
13.8, 4.5 Hz, 1H, benzyl-CH2), 4.71 (ddd, J = 10.2, 8.2, 4.5 Hz, 1H, Tyr-α-CH), 6.63 (d, J = 8.5 Hz, 
2H, ArH), 7.04 (ddd, J = 7.4, 1.2, 1.2 Hz, 1H, ArH), 7.06 (d, J = 2.6 Hz, 1H, ArH), 7.13 (d, J = 8.5 
Hz, 2H, ArH), 7.30 (dd, J = 8.6, 7.4 Hz, 2H, ArH), 7.59 (dd, J = 8.6, 1.2 Hz, 2H, ArH), 8.35 (d, J = 
8.2Hz, amide-NH), 9.17 (s, 1H, phenol-OH), 10.16 (s, 1H, Ar-amide-NH), 12.63 (d, J = 2.6, 1H, 
pyrrole-NH) ppm. 13C NMR (DMSO-d6, 100 MHz): δ 29.02, 47.67, 90.56, 96.92, 105.60, 106.72, 
112.12, 115.98, 118.82, 119.39, 120.23, 121.88, 129.74, 147.80, 151.76, 162.74 ppm. IR (ATR): ν 
3265, 1596, 1497, 1443, 1414, 1391, 1311, 1229, 1171, 751 cm-1. MS (ESI): m/z 506.0 ([MH+2]-, 
100), 504.0 ([MH]-, 51.4), 508 ([MH+4]-, 48.6). HRMS (ESI) for C20H16N3O3Br2: calculated, 
503.9564; found, 503.9558. RP-HPLC purity: 95%. ee = 0% 
1-((4,5-dibromo-1H-pyrrole-2-carbonyl)-L-tyrosyl)piperidine-4-carboxamide (13h) 
Compound 13a was prepared from 12 and isonipecotamide. The oily residue was purified by flash 
column chromatography, mobile phase: DCM : MeOH = 9: 1 to yield white crystals. Yield 47%. mp: 
168 – 172°C. 1H NMR (DMSO-d6, 400 MHz): δ 1.21 – 1.44 (m, 2H), 1.54 – 1.72 (m, 2H), 2.21 – 2.32 
(m, 1H), 2.70 – 2.90 (m, 3H), 2.98 – 3.09 (m, 1H), 3.88 – 3.98 (m, 1H), 4.20 – 4.37 (m, 1H), 4.91 – 
4.99 (m, 1H, Tyr-α-CH, Tyr-α-CH'), 6.61 (d, J = 8.3 Hz, 2H, ArH, ArH'), 6.77 (s, 1H, amide-NH2), 
6.80 (s, 1H, amide-NH2'), 7.04 (d, J = 8.3 Hz, 2H, ArH, ArH'), 7.07 (d, J = 2.7 Hz, 1H, ArH, ArH'), 
7.23 (s, 1H, amide-NH2), 7.24 (amide-NH2'), 8.36 (d, J = 8.2 Hz, amide-NH), 8.43 (d, J = 8.2 Hz, 
amide-NH'), 9.16 (s, 1H, phenol-OH), 9.17 (s, 1H, phenol-OH'), 12.61 (d, J = 2.7 Hz, 1H, pyrrole-
NH), 12.67 (d, J = 2.7 Hz, pyrrole-NH') ppm. IR (ATR): ν 3186, 1609, 1544, 1511, 1447, 1378, 1213 
cm-1. MS (ESI): m/z 541.0 ([MH+2]-, 100), 539.0 ([MH]-, 51.4), 543.0 ([MH+4]-, 48.6). HRMS (ESI) 
for C20H21N4O4Br2: calculated, 538.9935; found, 538.9945.	[𝛼]$%& = -6.85 (c 1.00, DMF). RP-HPLC 
purity: 99% 
Biology assay methods 
E. coli and S. aureus DNA Gyrase ATPase assay 
In vitro inhibitory activity screening and determination of IC50 values on E. coli and S. aureus Gyrase 
was performed on black streptavidin-coated 96-well microtiter plates (Thermo Scientific Pierce) as 
  
previously reported protocol.[22,25] The plate was first rehydrated with the wash buffer supplied (20 
mM Tris-HCl (pH 7.6), 137 mM NaCl, 0.01% (w/v) BSA, 0.05% (v/v) Tween 20). Biotinylated 
oligonucelotide was immobilized onto the wells. The excess of oligonucleotide was then washed off 
and the enzyme assay carried out in the wells. The final reaction volume of 30 µL in buffer (35 mM 
Tris HCl, pH 7.5; 24 mM KCl; 4 mM MgCl2; 2 mM DTT; 1.8 mM spermidine; 1 mM ATP; 6.5% 
(w/v) glycerol; 0.1 mg/mL albumin) contained 1.5 U of DNA gyrase from E. coli or S.aureus, 0.75 µg 
of relaxed pNO1 plasmid, and 3 µL of inhibitors solution in 10% DMSO and 0.008% Tween 20. 
Reactions were incubated for 30 min at 37°C and, after addition of the TF buffer (50 mM NaOAc pH 
5.0, 50 mM NaCl and 50 mM MgCl2), which terminated the enzymatic reaction, for another 30 min at 
room temperature to allow triplex formation (biotin−oligonucleotide− plasmid). The unbound plasmid 
was then washed off using TF buffer, and a solution of SybrGOLD stain in T10 buffer (10 mM Tris × 
HCl, pH 8.0, and 1 mM EDTA) was added. After mixing, the fluorescence (excitation, 485 nm; 
emission, 535 nm) was read using a BioTek’s Synergy H4 microplate reader. Preliminary screening 
was performed at inhibitor concentrations of 100 and 10 µM. For the most potent compounds, IC50 
was determined with seven concentrations of the inhibitors. IC50 values were calculated using 
GraphPad Prism software and represent the concentration of inhibitor where the residual activity of the 
enzyme is 50% in three independent measurements; the final result is given as their average value. 
Novobiocin (IC50 = 0.17 µM (lit.0.08 µM44) for E. coli DNA gyrase and IC50 = 0.041 µM (lit. 0.01 
µM44) for S. aureus DNA gyrase) were used as a positive control.  
E. coli and S. aureus Topoisomerase IV ATPase assay 
In vitro inhibitory activity screening and determination of IC50 values on E. coli and S. aureus 
topoisomerase IV was performed on the black streptavidin-coated 96-well microtiter plates (Thermo 
Scientific Pierce) as previously reported protocol.[22,25] The plate was first rehydrated with the 
supplied wash buffer (20 mM Tris-HCl (pH 7.6), 137 mM NaCl, 0.01% (w/v) BSA, 0.05% v/v) 
Tween 20), and biotinylated oligonucelotide was immobilized onto the wells. The excess of 
oligonucleotide was then washed off, and the enzyme assay carried out in the wells. The final reaction 
volume of 30 µL in buffer (40 mM HEPES KOH (pH 7.6), 100 mM potassium glutamate, 10 mM 
magnesium acetate, 10 mM DTT, 1 mM ATP, 0.05 mg/mL albumin) contained 1.5 U of 
topoisomerase IV from E. coli or S. aureus, 0.75 µg of supercoiled pNO1 plasmid, and 3 µL of 
inhibitors solution in 10% DMSO and 0.008% Tween 20. Reactions were incubated for 30 min at 37 
°C, and after addition of the TF buffer (50 mM NaOAc, pH 5.0, 50 mM NaCl and 50 mM MgCl2), 
which terminated the enzymatic reaction, for another 30 min at room temperature to allow triplex 
formation (biotin−oligonucleotide−plasmid). The unbound plasmid was then washed off using TF 
buffer and the solution of SybrGOLD stain in T10 buffer (10 mM Tris-HCl pH 8.0 and 1 mM EDTA) 
was added. After mixing, fluorescence (excitation, 485 nm; emission, 535 nm) was read using a 
  
BioTek’s Synergy H4 microplate reader. Preliminary screening was performed at inhibitor 
concentrations of 100 and 10 µM. For most potent compounds, IC50 was determined with seven 
concentrations of the inhibitors. IC50 values were calculated using GraphPad Prism software and 
represent the concentration of inhibitor where the residual activity of the enzyme is 50% in three 
independent measurements; the final result is given as their average value. Novobiocin (IC50 = 11 µM 
(lit. 10 µM44) for E. coli topoisomerase IV and IC50 = 27 µM (lit. 20 µM44) for S. aureus 
topoisomerase IV) was used as a positive control. Esherichia coli DNA Gyrase ATPase Assay. 
Compounds were diluted in DMSO and water to give 2 mM concentration in 50% DMSO, then 
serially diluted in 50% DMSO/water. Then 10 µL was added to a final assay volume of 100 µL, giving 
a final DMSO concentration in the assays of 5% (v/v). Compounds were tested between either 200 and 
0.005 µM or 25 and 0.0001 µM. Controls also contained a final concentration of 5% DMSO. E. coli 
gyrase ATPase activity (Inspiralis) was measured in a linked assay which follows the hydrolysis of 
ATP via the conversion of NADH to NAD+. E. coli DNA gyrase (10 µL of 500 nM) was incubated at 
25 °C in a final volume of 100 µL containing 1× assay buffer (50 mM Tris·HCl (pH 7.5), 1 mM 
EDTA, 5 mM MgCl2, 5 mM DTT, 10% (w/v) glycerol)), 800 µM phosphoenolpyruvate, 400 µM 
NADH, 1.5 µL of phosphokinase/lactate dehydrogenase (PK/LDH) enzyme mix, and 0.36 µM linear 
pBR322 plus or minus inhibitors. The order of addition to the wells was buffer/water/DNA mix, then 
compounds, and then the enzyme. This was equilibrated and the A340 measured for 10 min at 25 °C. 
Reactions were then initiated by the addition of ATP (Mg2+) to 2 mM and the decrease in A340 
measured over time. Raw data were collected as a change in OD340 with time (values quoted as milli 
OD340/min) and converted to A % of the 100% control (enzyme in the absence of inhibitors) after 
subtraction of the background (no enzyme) rate. These were analyzed using SigmaPlot Version 12.5 
(2014). 
Determination of Antibacterial Activity.  
Antimicrobial assays were performed by the broth microdilution method following the guidelines of 
the Clinical and Laboratory Standards Institute (CLSI; Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standards − Ninth Edition; M07-
A9, Vol. 32, No. 2). Primarily the following CLSI recommended quality control strains for 
susceptibility testing were used in the antibacterial assays: Enterococcus faecalis (Gram positive, 
ATCC 29212), Staphylococcus aureus (Gram positive, ATCC 25923), Escherichia coli (Gram 
negative, ATCC 25922), and Pseudomonas aeruginosa (Gram negative, ATCC 27853). In addition, E. 
coli tolC::Tn10, efflux deficient strain lacking functional tolC gene, and E. coli imp4213::Tn10 strain 
with altered permeability of the outer membrane, were used. Primary screening of compounds against 
the ATCC strains was initially carried out at a final concentration of 50 µM (n = 3). Compounds that 
showed >50% inhibition in the primary screen were tested further at several concentrations to confirm 
  
the activity and to determine MIC values. The compounds were further assayed against the E. coli 
strains in 10 2-fold dilutions starting from 256 µg/mL concentration. Azithromycin (USP, cat. 
1046056), ciprofloxacin (USP, cat. 1134313 or ICN Biomedicals, Inc.) and Meropenem (USP, cat. 
1392454) were used as standard antibiotics. 
Surface Plasmon Resonance (SPR) Measurements.  
Surface plasmon resonance (SPR) measurements for compounds were performed on a BiacoreX 
machine using CM5 sensor chip (Biacore, GE Healthcare) as previously reported protocol.[22,25] The 
system was primed twice with running buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 
0.005% surfactant P20). The G24 protein was immobilized on the second flow cell of a sensor chip 
CM5 using the standard amino coupling method. Briefly, the carboxymethylated dextran layer was 
activated with a 7 min pulse of 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) mixed in a 1:1 ratio. Protein was diluted to the final concentration of 50 
µg/mL in 10 mM sodium acetate (pH = 4.5) and injected in two short pulses to reach the final 
immobilization level around 17400 response units. Finally, the rest of the surface was deactivated with 
a 7 min injection of ethanolamine. The first flow cell was activated with EDC/NHS and deactivated 
with ethanolamine and served as a reference cell for subtraction of nonspecific binding. Analytes were 
prepared as DMSO 100× stock solutions and were diluted with a running buffer prior to the injection. 
They were injected at a flow rate of 30 µL/min for 90 s, and dissociation was monitored for an 
additional 120 s. Because the dissociation of analytes from the ligand was rapid, no regeneration 
protocol was needed. For the titration of analytes, the 1% of the DMSO was added to the running 
buffer in order to diminish the difference in refractive index between the samples and running buffer. 
Selected compounds 3, 24, 25, 32, 35, 36, and 43 were tested at at least eight different concentrations 
(depending on their solubility) in three parallel titrations. The sensorgrams were analyzed using 
BiaEval software (Biacore, GE Healthcare). Equilibrium binding responses were determined from the 
binding levels 5 s before the stop of the injection. Kd values were determined by fitting of the data to a 
1:1 steady state binding model as described in results. 
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Design, Synthesis and Evaluation of Tyrosine-Based DNA Gyrase B Inhibitors with Antibacterial 
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Cmp. R 
IC50 (µM) GyrB MIC90 (µg mL-1) 
E. coli S. aureus S. aureus E. faecalis 
8a COOMe 40 >250 14 28 
13e OH 13 28 38 38 
A series of novel tyrosine-based inhibitors of DNA gyrase B (GyrB), were designed, synthesized and 
evaluated against DNA gyrase and DNA topoisomerase IV. Compounds 8a and 13e, which inhibited E coli 
and S. aureus GyrB and displayed inhibitory activity against the growth of S. aureus and E. faecalis were 
identified as promising compounds for further structural optimization. 
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Figure 1. Representative examples of oroidin and GyrB inhibitors. 
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Figure 2. Structure and modifications of the designed inhibitors. 
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Scheme 1. Reagents and conditions: (i) Boc2O, dioxane/water 1/1, 0°C, 24h, 90%; (ii) methyl 3-
aminobenzoate, DCC, HOBt, CH2Cl2/DMF  1/1, 0°C to r.t., 24h, 56%; (iii) HCl(g), THF, 0°C, 20 min, 98%; 
(iv) for 8a,8 c, 8d: RCOCCl3, Na2CO3, DMF, 40°C, 24h, 20-74%; (v) 4,5-dichloro-2-trichloroacetyl-1H-
pyrrole (for 8b), indole-2-carboxylic acid (for 8e), indazole-3-carboxylic acid (for 8f), EDC, HOBt, NMM, 
DMF, 0 °C to r.t., 24h, 39–50%; (vi) 2M LiOH, H2O/THF=1/1, r.t., 2.5h, 95%, (vii) HCl.
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Scheme 2. Reagents and conditions: (i) 4,5-dibromopyrrole-2-carboxylic acid, EDC, HOBt, NMM, DMF, 0 
°C to r.t., 16h, 79%; (ii) LiOH, H2O/THF = 1/1, r.t., 1.5h, 95%, (iii) HCl; (iv) for 13a-d, 13h: R1NH2, EDC, 
HOBt, NMM, DMF, 0 °C to r.t., 16h, 45-75%, (v) for 13e-g: Ar-NH2, EDC, HOBt, DMAP, NMM, DMF, 0 
°C, 20 min to 60 °C, 16h, 14-53%; (vi) 1. 2M LiOH, H2O/THF, 25 °C, 24h, 95%, (vii) H+. 
 
